Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03238963
Other study ID # 1386-0012
Secondary ID 2016-002971-9113
Status Completed
Phase Phase 2
First received
Last updated
Start date September 19, 2017
Est. completion date May 14, 2020

Study information

Verified date March 2021
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative diabetic retinopathy (NPDR) (DRSS level 47) or severe Non-proliferative diabetic retinopathy (NPDR) (DRSS level 53), without Center-involved diabetic macular edema (CI-DME)


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date May 14, 2020
Est. primary completion date May 14, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Of legal age (according to local legislation, usually = 18 years) at screening - Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use two methods of contraception with at least one of them being a highly effective method of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. - Diagnosis of diabetes mellitus (type 1 or type 2): --Documented diabetes by American Diabetes Association (ADA) and/or World Health Organization criteria - Glycosylated hemoglobin (HbA1c) = 12% at screening - Non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) in the study eye at screening with NPDR level 47 or level 53, as determined by the Central reading center (CRC) by using the DR severity scale (DRSS) - Best corrected visual acuity ETDRS letter score = 70 letters in the study eye at screening - Media clarity, pupillary dilation and individual cooperation sufficient for adequate retinal examination including fundus photographs and Optical Coherence Tomography (OCT) - Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Exclusion Criteria: - Cataract surgery performed within 6 months prior to screening or planned during the trial in the study eye; or any additional eye disease in the study eye that, in the opinion of the investigator,could compromise or alter visual acuity during the course of the study (e.g. vein occlusion, uncontrolled intraocular pressure (IOP) >24 mmHg on optimal medical treatment, glaucoma with visual field loss, uveitis or other ocular inflammatory disease,vitreomacular traction, monocular vision, history of ischemic optic neuropathy, or genetic disorders such as retinitis pigmentosa) - Active center-involved DME (CI-DME) on clinical examination and Optical Coherence Tomography (OCT) central subfield thickness in the study eye above 300 µm as measured by Optovue OCT or above 320 µm as measured by Heidelberg OCT - Anterior segment and vitreous abnormalities in the study eye that would compromise the adequate assessment of the best corrected visual acuity or an adequate examination of the posterior pole - Evidence of neovascularization on clinical examination including active neovascularization of the iris (small iris tufts are not an exclusion) or angle neovascularization in the study eye, ruled out by gonioscopy (documented in the last 4 weeks before screening or performed at screening) - Prior pan-retinal photocoagulation (defined as = 100 burns placed previously outside of the posterior pole) in the study eye - Treatment of either DME or DR with macular laser within 3 months prior to screening, or intraocular injections of medication within 6 months prior to screening, and no more than 4 prior intraocular injections in the study eye at any time in the past - Patients treated with Monoamine Oxidase (MAO) inhibitors or drugs that may have potential side effects due to MAO inhibition - Current or planned, during the trial, use of medications known to be toxic to the retina, lens or optic nerve, or cause vision loss - Patients who must or wish to continue the intake of other restricted medications or any drug considered likely to interfere with the safe conduct of the trial - Estimated Glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening, or where the investigator expects filtration rate is likely to drop below 60 mL/min/1.73m2 during the trial - Alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.0-fold the upper limit of normal, or total bilirubin > 1.5x upper limit of normal. - Uncontrolled arterial hypertension defined as a single measurement of systolic blood pressure >180 mmHg, or two consecutive measurements of systolic blood pressure > 160 mmHg and/or diastolic blood pressure >100 mmHg on optimal medical regimen at screening. If blood pressure is brought to = 160/100 mmHg by antihypertensive treatment until randomization, individual can become eligible. - Wolff-Parkinson-White Syndrome, baseline QTc > 450 ms (Fridericia's formula), family history of long QT, or on medication prolonging QT time at screening or planned initiation during the trial - Diagnosis of a serious or unstable systemic or eye disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected life expectancy of less than 2 years are also excluded. - Active known or suspected chronic or relevant acute infections, such as HIV (Human Immunodeficiency Virus)\viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will be performed during screening. Patients with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active infection. - Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix. - Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study participant or unlikely to complete the trial - Known hypersensitivity to any component of the trial drug and/or allergy to fluorescein dye - Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned during the trial, e.g. hip replacement - Currently enrolled in another investigational drug trial, or less than 30 days or 5 times half-life of the investigational drug, whichever is longer, since ending another investigational drug trial from the screening visit in this trial or receiving other investigational treatment(s); patients participating in a purely observational trial will not be excluded. - Previous randomization in this trial - Women who are pregnant, nursing, or who plan to become pregnant while in the trial - Any other clinical condition that, in the opinion of the investigator, would jeopardize patient safety while participating in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BI 1467335
Once daily
Placebo
Once daily

Locations

Country Name City State
Austria LKH-Univ. Hospital Graz Graz
Greece Interbalkan Medical Center of Thessaloniki Thessaloniki
Italy Fondazione Centro San Raffaele del Monte Tabor Milano
Italy IRCCS Fondazione Bietti Roma
Norway Oslo Universitetssykehus HF, Ullevål sykehus Oslo
Portugal CHUC - Centro Hospitalar e Universitário de Coimbra, EPE Coimbra
Portugal Espaço Médico de Coimbra Coimbra
Portugal CHULC, EPE - Hospital Sto. António Capuchos Lisboa
Spain Hospital Dos de Maig Barcelona
Spain Hospital Vall d'Hebron Barcelona
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Miguel Servet Zaragoza
United Kingdom Bradford Royal Infirmary Bradford
United Kingdom Bristol Eye Hospital Bristol
United Kingdom Frimley Park Hospital Frimley
United Kingdom Moorfields Eye Hospital London
United Kingdom Royal Victoria Infirmary Newcastle upon Tyne
United Kingdom Hospital of St Cross Rugby
United Kingdom Sunderland Eye Infirmary Sunderland
United States Retina Research Institute of Texas Abilene Texas
United States Retina Research Center, PLLC Austin Texas
United States Retina-Vitreous Associates Medical Group Beverly Hills California
United States Charlotte Eye Ear Nose and Throat Associates, PA Charlotte North Carolina
United States Northwestern Medical Group Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States Trinity Research Dothan Alabama
United States Cumberland Valley Retina Consultants, PC. Hagerstown Maryland
United States Retina Consultants of Houston, PA Houston Texas
United States Raj K. Maturi, MD PC Indianapolis Indiana
United States New York Eye and Ear Infirmary of Mount Sinai New York New York
United States Florida Retina Institute Orlando Florida
United States Stanford University Medical Center Palo Alto California
United States University of Pennsylvania Philadelphia Pennsylvania
United States Retinal Research Institute, LLC Phoenix Arizona
United States NJRetina Teaneck New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Austria,  Greece,  Italy,  Norway,  Portugal,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period Percentage of participants with any ocular adverse events over the on-treatment period was reported. On-treatment period: from first dose of study drug until end of follow-up period, up to 24 weeks.
Secondary Percentage of Participants With at Least 2 Steps Improvement From Baseline in the Study Eye on the Diabetic Retinopathy Severity Scale (DRSS) at Week 12 7-field or modified 4-field digital fundus photographs was obtained from both eyes by a qualified person according to the imaging manual to collect all data for the assessment of the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS). The images was sent to the independent central reading center who performs the grading on the basis of the DRSS. The DRSS ranges from level 10 (Diabetic retinopathy absent) to level 85 (advanced proliferative Diabetic retinopathy). At baseline and at Week 12.
Secondary Percentage of Participants With Adverse Events Other Than Ocular Adverse Events Over On-treatment Period Percentage of participants with adverse events other than ocular adverse events over on-treatment period was reported. On-treatment period: from first dose of study drug until end of follow-up period, up to 24 weeks.
See also
  Status Clinical Trial Phase
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Completed NCT04905459 - ARDA Software for the Detection of mtmDR
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT05022615 - Comparing 3 Imaging Systems
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT03702374 - Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04009980 - Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus. N/A
Completed NCT02924311 - Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
Not yet recruiting NCT06257082 - Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities N/A
Not yet recruiting NCT05452993 - Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography N/A
Withdrawn NCT02812030 - Aflibercept for Retinopathy in the Real World N/A
Completed NCT02391558 - Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography N/A
Active, not recruiting NCT02330042 - OCT Biomarkers for Diabetic Retinopathy
Active, not recruiting NCT02353923 - OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A

External Links